Conformation-dependent anti-amyloid oligomer antibodies (Q36625938)

15 August 2017

Conformation-dependent anti-amyloid oligomer antibodies (English)

1 reference

15 August 2017

1 reference

Rakez Kayed

1

1 reference

PubMed ID

17046404

15 August 2017

Charles G Glabe

series ordinal

2

1 reference

PubMed ID

17046404

15 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

15 August 2017

Methods in Enzymology

1 reference

15 August 2017

413

1 reference

15 August 2017

326-344

1 reference

Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Pauling and Corey's alpha-pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Propagating structure of Alzheimer's beta-amyloid(10-35) is parallel beta-sheet with residues in exact register

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Rationalization of the effects of mutations on peptide and protein aggregation rates.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Designing conditions for in vitro formation of amyloid protofilaments and fibrils

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Mechanism of prion propagation: amyloid growth occurs by monomer addition

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Protein misfolding, evolution and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

The structural basis of protein folding and its links with human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Prediction of the Absolute Aggregation Rates of Amyloidogenic Polypeptide Chains

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

A conformation change in the carboxyl terminus of Alzheimer's Abeta (1-40) accompanies the transition from dimer to fibril as revealed by fluorescence quenching analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Observation of metastable Abeta amyloid protofibrils by atomic force microscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Antibody-mediated resolution of light chain-associated amyloid deposits.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Solid Phase Synthesis of Peptide C-Terminal Thioesters by Fmoc/t-Bu Chemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Alternative conformations of amyloidogenic proteins govern their behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Neurodegenerative disease: amyloid pores from pathogenic mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Kinetic theory of fibrillogenesis of amyloid beta-protein

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Formation of Mixed Fibrils Demonstrates the Generic Nature and Potential Utility of Amyloid Nanostructures

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Dimeric transthyretin variant assembles into spherical neurotoxins.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Nanoparticles, Proteins, and Nucleic Acids: Biotechnology Meets Materials Science

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Conformational Abs recognizing a generic amyloid fibril epitope

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Human lysozyme gene mutations cause hereditary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Cerebral hemorrhage after passive anti-Abeta immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Structural properties of Abeta protofibrils stabilized by a small molecule.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

Methodological and chemical factors affecting amyloid beta peptide amyloidogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2806%2913017-7

7 January 2021

10.1016/S0076-6879(06)13017-7

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17046404